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GPCR-specific autoantibody signatures are
associated with physiological and pathological
immune homeostasis
Otavio Cabral-Marques et al.#
Autoantibodies have been associated with autoimmune diseases. However, studies have
identified autoantibodies in healthy donors (HD) who do not develop autoimmune disorders.
Here we provide evidence of a network of immunoglobulin G (IgG) autoantibodies targeting
G protein-coupled receptors (GPCR) in HD compared to patients with systemic sclerosis,
Alzheimer’s disease, and ovarian cancer. Sex, age and pathological conditions affect auto-
antibody correlation and hierarchical clustering signatures, yet many of the correlations are
shared across all groups, indicating alterations to homeostasis. Furthermore, we identify
relationships between autoantibodies targeting structurally and functionally related mole-
cules, such as vascular, neuronal or chemokine receptors. Finally, autoantibodies targeting
the endothelin receptor type A (EDNRA) exhibit chemotactic activity, as demonstrated by
neutrophil migration toward HD-IgG in an EDNRA-dependent manner and in the direction of
IgG from EDNRA-immunized mice. Our data characterizing the in vivo signatures of anti-
GPCR autoantibodies thus suggest that they are a physiological part of the immune system.
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More than a century after the immunologist Paul Ehrlichproposed his theory of horror autotoxicus based on theconcept that immunized animals did not produce
autoantibodies (aab) in response to their own blood or blood
from their own species1, a paradigm persists linking aab to the
development of autoimmune diseases2. However, aab have been
found in healthy donors (HD) at preclinical stages and even in
those who never develop autoimmune disorders3,4. Furthermore,
beneficial, naturally occurring aab that show protective effects
against the development of immune-mediated diseases, such as
type 1 diabetes and psoriasis, have recently challenged the
aforementioned paradigm5. The most common theories proposed
to explain aab production are based on molecular mimicry and
immune dysregulation4,6. However, these theories mainly aim to
integrate the mechanisms of aab production with the commonly
accepted paradigm that associates aab with autoimmune diseases.
Thus, they are unable to fully explain the occurrence of self-
reactive B cells in mice and humans7 and the production of
immunogobulin G (IgG) aab that are naturally present in sera
from HD. The generation of natural aab shares a common
ontogeny with that of conventional antibodies, as both depend on
the presentation of stimulatory antigens by dendritic cells to T
and B lymphocytes4,6. We hypothesize that, similar to the dys-
regulation of any biological process, such as the imbalance of
cytokine synthesis by T helper (Th) cells in several pathological
conditions8, the dysregulation of aab production and function
may lead to autoimmune diseases. Thus, we suspect that the
homeostasis of aab relationships, which are possibly a physiolo-
gical part of our immune system, may break down, causing
autoimmune disease.
We and other research groups have previously reported the
existence of functional aab targeting G protein-coupled recep-
tors (GPCRs) in patients with rheumatic diseases9. GPCRs are
the largest superfamily of integral membrane proteins in
humans10. GPCRs play an essential role in vertebrate physiol-
ogy by sensing the external environment of a cell and
responding to a variety of physiological stimuli11. For instance,
GPCRs coordinate the cellular behavior involved in host
immune responses12 by acting as chemokine receptors, thus
functioning as pivotal regulators of cell migration and cell
trafficking throughout the body. In this context, GPCRs have
been shown to interact with other essential physiological
molecules by, for instance, cross-communication with
growth factors and growth factor receptors by generating
transactivation signals that contribute to the control of cell
migration13.
Here, our aim is to employ a stepwise, integrated
systemic immunology approach to extensively characterize the
correlation signatures of anti-GPCR aab across multiple
chronic diseases and in a large cohort of healthy humans. We
find a network of aab in sera from HD that target GPCRs. These
aab also correlate with other aab directed against growth
factors, growth factor receptors, and signaling molecules. The
aab signatures are dependent on factors such as age, gender,
and pathological conditions and have both shared and diver-
gent components in a wide range of diseases (systemic lupus
erythematosus or SLE, granulomatosis with polyangiitis
or GPA, rheumatoid arthritis or RA, systemic sclerosis or SSc,
ovarian cancer or OC, and Alzheimer’s disease or AD). Speci-
fically, we also found that anti-GPCR aab targeting
human endothelin receptor type A (EDNRA) regulate neu-
trophil migration. Our data provide support to the concept that
anti-GPCR aab are natural components of human
biology. When the production of anti-GPCR aab becomes
dysregulated, they may trigger the development of autoimmune
diseases.
Results
Disease-specific signatures of aab targeting GPCRs. Since both
elevated and decreased concentrations of aab have been asso-
ciated with the development of immune-mediated diseases14–24,
we suspected that anti-GPCR aab are an intrinsic part of the
immune system after observing altered levels of multiple anti-
GPCR aab in sera from patients with different autoimmune dis-
eases, such as SLE, SSc, GPA, and RA, compared with healthy
subjects (Fig. 1a–c, Supplementary Fig. 1). Our analyses revealed
disease-specific signatures of aab concentrations compared with
those of healthy individuals. SLE patients displayed increased
concentrations of all 10 anti-GPCR aab tested. While the levels of
some anti-GPCR aab were similar between the HD and disease
groups, SSc and RA patients exhibited both elevated and
decreased aab concentrations, and patients with GPA frequently
demonstrated lower anti-GPCR aab concentrations compared
with HD. We also observed that aab directed against structurally
and functionally related molecules, such as anti-angiotensin II
receptor type 1 or AGT1R and EDNRA (Fig. 1d–i), cholinergic
receptor muscarinic (CHRM) 1–4 (Fig. 1j), protease-activated
receptors (coagulation factor II thrombin receptor or F2R and the
coagulation factor II thrombin receptor-like 1 or F2RL1)
(Fig. 1k), and chemokine (C-X-C) motif receptor 3 (CXCR3) and
4 (Fig. 1l), correlated strongly in HD. In this context, the asso-
ciation between aab targeting CXCR3 and CXCR4 remained
stable despite the presence of autoimmune diseases. However,
disease-specific changes among the other aab were identified.
While only SLE abrogated the normal interconnection between
anti-AGTR1 and anti-EDNRA (Fig. 1e–i), the correlation among
anti-CHRMs was reduced in SLE and GPA, whereas the part-
nership of aab directed against F2R and FRL1 was abolished in
SLE, SSc, and GPA.
Network-based view of aab targeting GPCRs. The aforemen-
tioned data suggested physiological relationships among aab. To
gain better insights into this field of investigation, we expanded
our study to include the analysis of HD sera for correlation
networks among anti-GPCR aab and other aab groups (e.g.,
growth factors and growth factor receptors, as well as signaling
and neuronal molecules; Supplementary Tables 1 and 2). As
previously shown for a few types of aab15, we observed that HD
aab targeting GPCRs strongly correlated with each other and with
aab targeting growth factors and growth factor receptors (Fig. 2a).
While gender and age slightly modified the relationship between
sets of aab from HD (Fig. 2c–f), the results were markedly dif-
ferent in sera from patients with SSc (Supplementary Table 2,
cohort 1; Fig. 2b), a disease for which anti-GPCR aab-associated
immunopathological mechanisms have been extensively
investigated9,19. For instance, aab correlations changed, including
those between aab targeting AGTR1, epidermal growth factor
receptor (EGFR), and vascular endothelial growth receptors
(FLT1 and KDR) and the other aab.
To identify changes in the aab relationships of patients with
non-autoimmune diseases, we analyzed aab correlations in
conditions that are known to be associated with gender and age
but of clearly different etiologies, such as OC and AD. In OC,
the interconnections among aab (Supplementary Table 2, aab
dataset 2) exhibited only a slight difference in comparison to
HD (Fig. 3a, b). In patients suffering from AD, the global
interconnection among aab-targeting GPCRs, growth factors,
growth factor receptors, and neuronal molecules (Supplemen-
tary Table 2, aab dataset 3), which have been previously
associated with cognitive dysfunction and depression25, were
only marginally different (Fig. 3c, d). Of note, aab targeting
neuronal receptors (dopamine, adrenergic, muscarinic, and
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serotonin receptors) showed strong intragroup relationships in
both HD and patients with AD, further indicating the presence
of physiologically related aab. While aab concentrations and
their associations with clinical data from the AD cohort have
been previously described25, detailed information regarding aab
levels in sera from SSc and OC patients and correlations with
clinical characteristics are being prepared.
We suspected that the alterations in aab networks described
above, which were more dramatic in sera from SSc patients, could
be an effect of changes in the distribution pattern of aab
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concentrations across the different cohorts of HD and disease
categories. To test this possibility, we calculated the Gini
coefficient of inequality with bootstrap confidence intervals,
which is the most popular metric for operationalizing inequality,
defined by the mean of the absolute difference in all pairs of
individuals for some measurements26. This approach revealed
that the changes observed in aab relationships, as shown by the
circular plots (Fig. 2 and Fig. 3) according to gender, age, and
disease, reflected the distribution pattern of aab concentrations
across the different investigated groups (Fig. 4). In accordance
with the Gini index approach, linear discriminant analysis (LDA)
of aab across the HD and disease groups highly discriminated HD
and SSc patients when compared to the moderate differences
between HD vs. OC and HD vs. AD (Supplementary Figure 2).
Hierarchical clustering signatures of anti-GPCR aab. To further
characterize the relationships among aab, we performed hier-
archical clustering analysis of aab correlations. For comparison,
Fig. 5 shows nonclustering heatmaps of the correlations among
all three aab datasets (Supplementary Table 2) investigated in the
HD and disease cohorts. The hierarchical clustering analysis of
aab correlations revealed several clusters (modules) of aab in sera
from HD (Fig. 6). Dendrograms of the correlation matrices
exhibited a strong proximity of aab targeting molecules that are
closely related in terms of structure and function, such as
AGTR1/EDNRA, CXCR3/CXCR4, CHRMs, and β-adrenergic
receptors (ADRB), as well as between growth factors and growth
factor receptors. Aab from healthy females and males below and
above 65 years of age, the latter age group representing the life
period most associated with increased generation of natural aab3,
formed major cluster modules (a term previously well char-
acterized in the context of correlation network analysis27). We
found several positive and negative clusters of correlations
between various aab groups, supporting the modification of aab
relationships by age and gender. In the presence of SSc (Fig. 6),
AD, and OC (Supplementary Figure 3a–b), we observed disease-
specific formation of aab clusters when compared to the HD
subgroups. However, markedly changed aab hierarchical clus-
tering was only observed when comparing aab from the SSc
cohort (composed mainly of females, mean age 56.9 ± 13 years) to
HD. Aab from the SSc and OC cohorts were located in the bot-
tom right corner of the correlogram matrix near the clusters of
aab from HD females above and below 65 years of age, respec-
tively. Due to the small number of males aged >65 years in HD
cohort 3, which was a limitation of our study, we did not perform
subgroup analyses of HD cohort 3 according to age in the cor-
relogram matrix of the associations among aab from AD patients.
Hierarchical clustering analysis of aab in HD alone (Supple-
mentary Table 1, aab dataset 1) and from HD compared with
patients with SSc, OC, or AD when not subgrouped by gender
and age are shown in Supplementary Figure 3c–e. Taken together,
these findings suggest that gender, age, and pathological
condition influence the hierarchical clustering signatures formed
by aab.
Relationships among anti-GPCR aab. To integrate the analysis
performed using three cohorts of HD and patients diagnosed with
different diseases and using different aab datasets, we performed a
multistudy factor analysis (MSFA)28. In agreement with our
hypothesis that aab acting under normal physiological conditions
may become dysregulated under the influence of different vari-
ables, the MSFA revealed the presence of common and specific
latent factors when comparing HD to patients with selected dis-
eases (Fig. 7). This finding implies that the specific factors we
observed in the HD and disease cohorts are involved in particular
physiological and pathological mechanisms, respectively. In
contrast, the common (shared) factors suggest physiological
functions that are regulated by aab but not affected by the disease
state.
Next, since an interactome database for aab is currently not
available, we reverse-engineered aab functions through in silico
evaluation of aab target interactions to gain insights into the
dynamics of a putative aab network. Network mapping of aab
targets (Supplementary Table 2, dataset 1) displayed multiple
associations among GPCRs, growth factors, and growth receptors,
suggesting an enriched network (Supplementary Figure 4a) in
which EDNRA plays a central role. Enrichment gene ontology
(GO) analysis indicated the regulation of cell migration
(GO:0030334) as a strongly significant function among the
biological processes involved in this network of aab targets
(Supplementary Figure 4b).
Chemotactic activity of anti-EDNRA aab. Based on our in silico
analysis, we assessed the effect of IgG from HD (HD-IgG)
without and with EDNRA inhibition on the migration of
neutrophils before testing the hypothetical chemotactic activity
of anti-EDNRA aab. Neutrophils are the most abundant per-
ipheral blood-circulating leukocytes and the first white cells to
invade sites of inflammation, that is, during infection or fol-
lowing tissue damage29. Neutrophils, which express EDNRA
(Fig. 8a and Supplementary Figure 5), migrated toward HD-IgG
in an EDNRA-dependent manner (Fig. 8b). The requirement of
EDNRA for HD-IgG-induced migration was confirmed using
Colo357 cells, as shown in Supplementary Figure 6. The HD-
IgG-mediated chemotactic activity was mainly induced by the
Fab fragment of IgG (Fig. 8c), although the Fc fragment showed
weak chemotactic properties as well. Notably, the effect of
EDNRA inhibition on cell migration by sitaxsentan was not due
to cytotoxic effects since neutrophils in vitro did not display
signs of apoptosis or necrosis when EDNRA was inhibited by
sitaxsentan (Supplementary Figure 7). HD-IgG did not affect
other physiological functions, such as the neutrophil or
monocyte oxidative burst or lymphocyte proliferation (Sup-
plementary Figure 8; both performed as previously
Fig. 1 Relationships among autoantibodies in health and autoimmune diseases. a The graphic summarizes anti-GPCR autoantibodies (aab) in healthy
donors (HD), which showed significantly increased or decreased concentrations when compared to those in the disease cohorts (systemic lupus
erythematosus or SLE, systemic sclerosis or SSc, granulomatosis with polyangiitis or GPA, and rheumatoid arthritis or RA). Further details are shown in
Supplementary Figure 1. The x-axis represents healthy controls. Graphics display concentrations of aab directed against b EDNRA and c CHRM2. The
median with interquartile range is shown in red. *p≤ 0.05 (Mann–Whitney test). Linear regression graphics exhibit the correlation between anti-EDNRA
and anti-AGTR1 aab in sera from d HD, e SLE, f SSc, g GPA, and h RA. Heatmaps of aab vs. aab correlations demonstrate the spectrum of relationships
among aab targeting i EDNRA and AGTR1; j CHRMs; k F2R and FLR1; and l CXCR3 and CXCR4 (for nomenclature, see Supplementary Table 2, aab dataset
1). The bar ranging from yellow to blue (−0.3 to 1) represents negative to positive correlations, respectively. In the correlation matrix, each small square
represents a pairwise correlation between aab, as exemplified by d–h. The correlation matrices used to perform the hierarchical correlograms shown in
Fig. 1i–l are provided as source data
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described30,31). In addition, the HD-IgG used was endotoxin-
free, as demonstrated by endotoxin testing (PTS cartridge
<0.05 EU/ml). Considering the central role of interleukin-8 (IL-
8) as an important chemokine that regulates neutrophil
migration29, we were able to show that HD-IgG triggered IL-8
production by peripheral blood mononuclear cells (PBMCs)
(Fig. 8d), which also express EDNRA32. The spontaneous IL-8
synthesis by PBMCs strongly correlated with EDNRA expres-
sion (Fig. 8e). These findings suggest that HD-IgG controls the
trafficking of neutrophils directly via chemotactic mechanisms
and indirectly by triggering IL-8 production.
To investigate a possible chemotactic effect of anti-EDNRA aab
on cell migration, C57BL/6 mice were immunized with
membrane extracts of Chinese hamster ovary (CHO) cells
overexpressing human recombinant EDNRA (Fig. 8f), a molecule
that is highly conserved between humans and mice, as well as
across several other species (Supplementary Figure 9). EDNRA-
immunized mice produced high concentrations of aab targeting
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Fig. 2 Effects of gender, age, and systemic sclerosis on autoantibody correlations. We analyzed the relationships among the different autoantibodies (aab)
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EDNRA (Fig. 8g). Human neutrophils migrated toward IgG from
both control and EDNRA-immunized mice. However, IgG from
the latter group showed stronger chemotactic activity and
induced the formation of neutrophil aggregates when compared
to IgG from non-immunized mice (Fig. 8g).
Discussion
With the discovery of anti-GPCR aab in patients with allergic
rhinitis and asthma33 and the recognition that they play a role in
the pathogenesis of several disorders, such as rheumatic diseases9,
the physiological relevance of aab targeting GPCRs found in the
sera of HD9,34 remains poorly understood. While the function of
some of the aab reported herein and their value as disease bio-
markers are still under investigation16,24, other anti-GPCR aab,
such as those targeting EDNRA and AGTR1, were previously well
described. These studies utilized purely analytical approaches and
considered EDNRA and AGTR1 to be pathological agents that act
on different molecular targets by triggering intracellular GPCR
signaling9,15,35. The network-based analyses carried out in our
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Fig. 3 Effects of ovarian cancer and Alzheimer’s disease on autoantibody correlations. Graphics display the comparisons of a healthy donors (HD) and
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investigation revealed distinct signatures of anti-GPCR aab in HD
that are influenced by age, gender, and various diseases. In
addition, anti-GPCR aab from HD are possibly able to act as
regulators of GPCR-mediated mechanisms, as evidenced by the
chemotactic effects of human IgG and anti-EDNRA antibodies on
cell migration. Therefore, together with the previously demon-
strated effects of anti-GPCR aab on GPCR signaling15,35, our
findings suggest that aab targeting GPCR are newly recognized
components of human biology. These data are in accordance with
our recently developed novel SSc mouse model, which is based on
increasing the serum concentration of anti-AGT1R aab by
immunizing mice with human AGTR1 (manuscript submitted).
Therefore, our observations support the hypothesis that anti-
GPCR aab are natural components of the immune system and
may become dysregulated, triggering the development of auto-
immune diseases. This assumption is in accordance with the
emerging observation of the role of the immune system in
homeostasis beyond host defense36–40.
Here, we determined the correlation signatures of aab in health
and disease based on enzyme-linked immunosorbent assay
(ELISA), an approach that is widely used to determine the pre-
sence of aab that target GPCRs9. Although this method is well
established, there are limitations. The avidity and affinity of aab
to their target are not measured. Of note, aab avidity and affinity,
as well as aab isotype, can change the outcome of
antibody–antigen interactions and relevant biological processes
following binding. As such, some biological determinants of
harboring GPCR aab have not been measured for each aab in our
study, which may be potentially relevant for all patient groups,
including patients with autoimmune diseases. Consequently, it
will be important to investigate the characteristics of the aab
described above in HD to determine their influence on aab
physiology. For instance, low concentrations of aab could be
compensated by high binding affinity and vice versa. We are also
expanding our current findings by analyzing specific epitopes.
Furthermore, we are establishing experimental immunization
models to better understand the pathophysiology of aab targeting
GPCRs. Thus far, immunizations of mice with human AGTR1
and EDNRA have been successful, and reports will be published
in detail elsewhere. For instance, immunization with AGTR1, a
highly conserved receptor in humans and mice, increases func-
tional anti-AGTR1 ab levels. Such experimental immunization
also induces pathological SSc features, including interstitial lung
disease and skin fibrosis. Passive immune transfer studies would
be a relevant next step to determine whether anti-AGTR1 indeed
has pathogenic effects with respect to SSc. The presence of cir-
culating aab in HD that target self-antigens, such as GPCRs,
which are conserved among species3 and form network sig-
natures, expands our view of the immune system. The prevailing
concept of a functional immune system has focused on its role as
a guardian against invading pathogens. An evolving shift backing
off from this paradigm is derived from the notion that the
immune system has evolved not only to protect the host from
pathogens but also to maintain the immunological homeostasis of
the organism. As a consequence of internal tissue damage fol-
lowing infectious or noninfectious inflammation, this home-
ostasis can break down36–40. The current understanding of aab
function is evolving and includes the notion that aab provide and
maintain homeostatic functions through the binding of cellular
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antigens and consequently contribute to the clearance of apop-
totic cells41. Aab production could be modulated by changing
particular conditions, such as increasing or decreasing receptor
expression, as demonstrated by injection with CHO cells over-
expressing human EDNRA, thereby inducing anti-EDNRA anti-
body synthesis. Consequently, the production and effect of these
aab would depend on the level of receptor expression in specific
tissues. Thus, modulating receptor expression for target epitopes
on the cell membrane by aab-mediated endocytosis could provide
a mechanism for maintaining aab-mediated cellular homeostasis.
In addition, GPCR and growth factor receptors are not only
expressed by immune cells and different body tissues, they are
also present in extracellular vesicles, such as exosomes, which are
implicated in numerous pathologies, including cancer and
inflammatory diseases42. Therefore, exosomes could represent
another important physiological source for the stimulation of
anti-GPCR aab production that remains to be investigated.
From an evolutionary perspective, our findings are consistent
with the phenomenon that autoreactive B lymphocytes have not
been excluded by natural selection and can remain functionally
active5,7,43–46, producing aab that are ubiquitously present and
evolutionarily conserved3,47. This logic challenges the paradigm
that links aab exclusively with the triggering of autoimmunity.
Instead, a novel concept arises that considers anti-GPCR aab as
an integral part of the immune repertoire, the function of which
may broadly affect several biological mechanisms by targeting
GPCRs. The dysregulation of anti-GPCR aab relationships fol-
lowing uncontrolled tissue injuries in some pathological
conditions opens opportunities for new investigations in auto-
immune disease. Moreover, it will also be important in the future
to determine how anti-GPCR networks and signatures interact
with drugs, as GPCRs comprise almost one-third of all current
drug targets in clinical medicine48.
In conclusion, the presence of a physiological network of aab
directed against GPCRs in HD opens new avenues for the iden-
tification of new homeostatic mechanisms regulated by aab. In
this context, it is reasonable to suggest that physiological aab
against GPCRs9, such as functional aab targeting EDNRA15, and
other functional aab, such as those targeting growth factor
receptors including anti-PDGFR antibodies49 previously char-
acterized in patients with SSc, could also regulate a myriad of
biological mechanisms in synergism with endogenous
ligands50,51. These possibilities remain to be investigated in HD.
Further evaluation of these possible aab functions will not only
contribute to our understanding of the signaling systems involved
but also of the mechanisms that lead to autoimmune diseases and
subsequently the development of new and specific therapies.
Methods
Participants. We first measured the concentration of aab directed against 10
different GPCR in sera from patients with different autoimmune diseases who
underwent follow-up in the Department of Rheumatology at the University of
Lübeck and at the University Hospital Charité in Berlin. Patients with SLE (n=
249), SSc (n= 379), GPA (n= 128), and RA (n= 196) were included and diag-
nosed according to the established criteria52–55, and the concentrations of aab were
compared to those of HD (n= 197). Next, a total of 491 HD and patients with SSc
(n= 84), AD (n= 91), and OC (n= 207) (Supplementary Table 1, cohorts 1, 2,
and 3) classified according to previously established criteria55–57 participated in the
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study. Sera from SSc patients were provided by members of the Department of
Rheumatology at the University of Lübeck and the University Hospital Charité in
Berlin; the AD patients are being cared for by three participating Norwegian
centers (Rogaland and Hordaland counties and the dementia study in Western
Norway). Sera from OC patients were provided by Prof. Jalid Sehouli, Department
of Gynecology, the University Hospital Charité in Berlin, corporate member of
Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute
of Health. All HD and patients provided written consent to participate in the study,
which was performed in accordance with the Declaration of Helsinki and approved
by the ethics committees of the involved research centers.
Aab detection by ELISA. The methods to measure the aab have been previously
described in detail15,25. Briefly, individual serum aab were assessed using
commercially available solid-phase sandwich ELISA Kits according to the manu-
facturer’s instructions (all CellTrend GmbH, Luckenwalde, Germany). The aab
concentrations were calculated as arbitrary units (U) by extrapolation from a
standard curve of five standards ranging from 2.5 to 40 U/ml. The ELISAs were
validated according to the Food and Drug Administration’s Guidance for Industry:
Bioanalytical Method Validation.
Aab interaction network. Statistical and bioinformatics analyses of the obtained
aab data were performed using the free, open-source software package R58. The R
packages are described in the Reporting Summary. We used circle plot diagrams to
visualize the patterns of Spearman’s rank correlation coefficients between aab and
the Gini index coefficient26 to assess the distribution patterns of aab concentra-
tions. In addition, LDA of aab signatures was performed as previously described to
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Fig. 6 Hierarchical clustering of the autoantibody correlation signature. Correlogram matrix displays clusters (modules) of autoantibody (aab) correlations
in all healthy donors (HD) according to gender and age (< and ≥65 years old) compared with patients with systemic sclerosis (SSc; Supplementary Table 1,
cohort 1; Supplementary Table 2, aab dataset 1). Clusters of the correlations among aab are displayed in dendrograms on the top and side of the correlation
matrix. The bar ranging from yellow to blue (−0.6 to 0.9) represents negative to positive correlations, respectively. In the heat map matrix, each small
square represents the pairwise correlations between aab. The correlation matrix used to perform the hierarchical correlogram of SSc is provided as source
data
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discriminate the global aab signature of HD and patient groups59 as appropriately
recommended to analyze immunological data60. MSFA (described in detail below),
using a fast expectation conditional-maximization algorithm for the parameter
estimate28, was used to comprehend the correlation structure of the aab network.
This approach is a generalized version of factor analysis that is able to handle
multiple studies simultaneously to identify common and study-specific factors
shared by different studies28. MSFA considers all data at once in an integrated
approach, estimating parameters by maximum-likelihood analysis61. MSFA
allowed the identification of specific and shared factors among aab from three
different cohorts of HD (Supplementary Table 1) analyzed for three aab datasets
(Supplementary Table 2) and in comparison to cohorts of patients with SSc, AD,
and OC, respectively. Hierarchical clustering of Pearson's correlations of aab62 was
carried out using the Perseus software63 (MaxQuant, v1.11, Martinsried, Germany)
to assess the correlation signatures of aab. When indicated, HD were subdivided
according to gender and age (< and ≥65 years of age), with the latter representing
the life period most associated with increased dysregulation of natural antibody
production3. In addition, we reverse-engineered the functions of aab through the in
silico evaluation of aab (aab dataset 1) target interactions using STRING64 and GO
analysis according to the Gene Ontology Consortium65 to gain insight into the
physiological roles66 of aab. Enrichment analysis of the GO biological processes
was considered significant when the false discovery rate/adjusted p value was ≤0.05.
IL-8 release. HD-IgG (0.5 mg/ml) was used as a standard in all experiments as
previously described32. In summary, after Fc-γ receptor blockade, 1 × 106 PBMCs
isolated from heparinized blood as previously described31,67 were activated by a
pool of heterologous purified IgG from 10 different HD. After 20 h of culture in the
absence or presence of the 100 µM EDNRA antagonist sitaxsentan (Pfizer Inc.,
New York, NY, USA), the supernatants were harvested and evaluated for the
presence of IL-8 using ELISA according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA).
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Fig. 7 Multistudy factor analysis of autoantibodies. The multistudy factor analysis (MSFA) was performed to analyze autoantibodies (aab) from healthy
donors (HD) compared with patients with a systemic sclerosis (SSc), b ovarian cancer (OC), and c Alzheimer’s disease (AD). Supplementary Tables 1 and
2 provide further details about the HD and patient groups, as well as the aab datasets analyzed. The images are heatmaps of estimated factor loadings of
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Migration assays. The capacity of antibodies to induce neutrophil chemotaxis was
analyzed using the transwell migration assay (24-well plate, Corning Inc., Corning,
NY, USA) as previously described32. For the analysis of HD-IgG-induced migra-
tion, neutrophils were isolated from heparinized blood by dextran sedimentation
followed by Ficoll-Hypaque centrifugation as previously described30. The purity,
based on CD15 expression, was always above 97%, as was the viability before the
migration assays. After Fc-γ receptor blockade with Human TruStain FcX Receptor
Blocking Solution (Biolegend, San Diego, CA, USA), the isolated neutrophils (0.2 ×
106) were transferred to the upper chamber, while RPMI containing total human
IgG, Fc, and Fab fragments (Merck, Darmstadt, Germany) or IgG from EDNRA-
immunized and control mice (kindly provided by Prof. Xinhua Yu and Prof. Frank
Petersen from the Research Center Borstel, Airway Research Center North, ARCN,
Members of the German Center for Lung Research DZL, Borstel, Germany) were
placed in the lower chamber of plates and incubated at 37 °C for 1 h. When
indicated, neutrophils were incubated before chemotaxis assays for 1 h in the
absence or presence of 100 µM of the EDNRA antagonist sitaxsentan. Migrated
neutrophils present in the bottom of the transwell plates were transferred to a 96-
well plate and counted (cells/µl) by flow cytometry using a CytoFLEX Flow Cyt-
ometer (Beckman Coulter, Indianapolis, IN, USA) by gating on neutrophils
according to size (forward scatter, FSC) and granularity (side scatter, SSC) to
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exclude cell debris. Images of the cells on the bottom surface of the transwell plates
were obtained using a fluorescence microscope (EVOS FL Cell Imaging System,
Oakwood, OH, USA). The migration index was calculated in relation to the
spontaneous (medium) migration (index 100). In addition, cell migration toward
HD-IgG in an EDNRA-dependent manner was further analyzed using a cell-based
Oris™ migration assay with human pancreatic carcinoma Colo357 cells according
to the manufacturer’s instructions as previously described in detail68. Briefly,
Colo357 cells were cultured and allowed to migrate (in the presence or absence of
10–4 M sitaxsentan) into the free space in the middle of the well for 48 h. The cells
were fixed and stained with a DiffQuick Cell Staining Kit (Medion Diagnostics,
Gräfelfing, Germany). After staining, an Oris™ detection mask was clipped to the
bottom of the plate, and images were obtained with a blackfly camera on an
Axioskop HBO 50 microscope. The migration area was determined by analyzing
the migration images with the Fiji module of the ImageJ software.
Analysis of EDNRA expression by flow cytometry. Neutrophils were analyzed
after red blood cell (RBC) lysis using a RBC lysis solution (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions, and PBMCs were isolated as
described above. The cells were stained for EDNRA expression using previously
reported antibodies (Supplementary Table 3) and procedures32,69. Briefly, neu-
trophils and monocytes were gated according to size (FSC) and granularity (SSC)
and based on the pattern of CD15 and CD14 expression (Supplementary Figure 8).
For median fluorescence intensity (MFI) values, an isotype control (Supplementary
Table 3) was used as described below to compensate for changes in the cytometry
instrument sensitivity. Since the neutrophils and monocytes were analyzed in two
different labs (University of Lübeck and Charité University Hospital, respectively),
the latter cell population was analyzed on a MACS Quant Cytometer (Miltenyi
Biotec) and the former using a CytoFLEX Flow Cytometer (Beckman Coulter,
Indianapolis, IN, USA). The MFI for EDNRA expression was obtained using the
FlowJo Software (Treestar Inc., Ashland, OR, USA). The CytoFLEX and MACS
Quant Flow cytometers were calibrated using Cytoflex Daily QC Fluorospheres
(Beckman Coulter, Indianapolis, IN, USA) and MACSQuant™ Calibration Beads
(Miltenyi Biotec, Bergisch Gladbach, Germany), respectively, according to the
manufacturer’s instructions. MFI was determined by controlling the daily technical
variability using a fluorochrome-conjugated isotype control antibody. Therefore, a
subtraction procedure70 was applied to obtain the EDNRA MFI density (MFI-
EDNRA/MFI isotype).
Data availability
A reporting summary for this article is available as a Supplementary Information
file. The source data underlying Fig. 1b–l, Fig. 6, Fig. 8, and Supplementary Fig-
ures 3B–3C are provided as a Source Data file. Additional data that support the
findings of this study are available from the corresponding author upon reasonable
request. All R packages used in this manuscript are described in the Reporting
Summary. The results of this study have been shared via Figshare and can be
accessed using the following link: https://figshare.com/s/c24828b4a6260b2e5531.
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